Skip to main content
Premium Trial:

Request an Annual Quote

Memo to Get Ready

The US Centers for Disease Control and Prevention has told states to prepare for widespread distribution of a SARS-CoV-2 vaccine by the beginning of November, CNBC reports.

It obtained a copy of a letter CDC Director Robert Redfield sent to governors that said the health agency had contracted with pharmaceutical company McKesson to distribute millions of vaccine doses to health departments and others across the country. According to CNBC, Redfield writes in the letter that, if need be, the CDC "asks you to consider waiving requirements that would prevent these facilities from being fully operational by November 1, 2020."

NPR adds that one of the planning documents outlines various scenarios for vaccine release. One scenario, for instance, describes the release of two vaccines beginning at the end of October, with about 2 million doses of "Vaccine A" and about 1 million doses of "Vaccine B" being ready by then and with increasing numbers of doses available through November and December, it adds.

However, as CNBC notes, it's unclear whether any vaccine will be ready for mass distribution by that point. NPR adds that three SARS-CoV-2 vaccines are in phase III trials in the US and that public health officials have said early 2021 is a more likely time frame for their availability.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.